US Food & Drug administration gives accelerated approval to drug that uses body’s immune system to fight cancer
The company estimates Imfinzi could eventually become a blockbuster product with peak sales of US$6.5bn.
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 43 of 55
AstraZeneca’s new drugs can’t come quick enough
Copycat competition for big sellers such as cholesterol-buster Crestor ate into first quarter revenues, which fell by 12% to US$5.54bn in the first-quarter.
Herencia Resources and Afarak gain, shares in Turbo Power Systems head south
Herencia Resources is a high riser among London's small caps today as it prepares a drill plan to enhance its copper projects
Synairgen believes interferon beta candidate has potential
The company, which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.
Circassia Pharmaceuticals posts big 2016 loss after allergy disappointments
Circassia booked restructuring costs and impairments of £80.0mln in 2016 leading it to report a pretax loss of £144.9mln, up from a £62.8mln loss in 2015
Archive
BHP Billiton and banks dominate big week for blue chips
Week ahead: Huge for blue chip announcements with four high street banks, the UK’s two pharma giants, mining titans Anglo and BHP and restaurant to coffee chain Whitbread just a few of those updating.
Archive
Back to the dog pound: Dogs of the Footsie outperform in 2017
At the end of January, John Harrington tweaked the famous investment strategy known as the Dogs of the Dow, and applied it to UK stocks. How are the investments doing?
Drugs giant AstraZeneca's recommendation cut by Jefferies
“We and consensus have been guilty of failing to reflect the impact of future revenue externalisation and asset disposals on revenue and earnings per share growth,” said analyst Jeffrey Holford.
Merck receives diabetes drug labelling setback
Merck received a Complete Response Letter from the US Food and Drug Administration on the use of Sitagliptin
Archive
Rookie Investor: Finding out the easy way the importance of a stop-loss
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
AstraZeneca’s diabetes drug data shows significant cut in death rates
A study of more than 300,000 people spanning six countries showed Farxiga significantly cut the risk of death or heart failure in diabetes sufferers
Investments and investor services
FTSE 100 ends little changed as UK lines up on Brexit grid
The druggies and miners were on offer early on – although the movements were barely perceptible on a lacklustre Monday morning.
Astra collaboration breathes new life into Circassia
The transaction provides an opportunity to transform Circassia's product portfolio and commercial presence.
Metal Tiger buoyed by strong response to partner's fund raise
Main share price risers and fallers in London at 4pm: Metal Tiger, Ilika
FDA deals another blow to AstraZeneca’s ZS-9 blood drug
ZS-9 is a treatment for hyperkalaemia – a condition where potassium levels in the blood are too high
Archive
Rookie Investor: The story so far
As I venture into the world of equity trading, here’s the background to my story and where I’m at now
FTSE shares end lower as sterling marks 8-week low vs dollar on Brexit jitters
FTSE 100 shares closed lower on Tuesday after investors turned edgy over Brexit plans which hit banking and retail shares as well as took sterling to an 8-week low against the US dollar
Hutchison China MediaTech reports record 2016 revenue as commercial sales rise
The biopharma company said it has made progress on the development of several cancer treatments